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Abstract 
 
Background: Exit-site infections remain a major clinical problem in peritoneal dialysis 
(PD). Although detailed descriptions about microbiologic epidemiology regarding exit-
site infections are found in the literature, little is known about the different risk factors 
associated with Gram positive and Gram negative infections.  Objective: To 
retrospectively evaluate the factors associated with the presence and clinical behavior 
of exit-site infections caused by Gram positive and Gram negative agents in PD patients. 
Methods: This study included all cases of PD catheter exit-site infections diagnosed in 
patients followed in a PD Unit during 2011 and 2012. Patients with exit-site infection 
caused by Gram positive and Gram negative agents were compared regarding 
demographic, clinical and analytical variables. This analysis was extended to specific 
episode etiologies (Staphylococcus aureus and Pseudomonas aeruginosa) and distinct 
clinical behaviours, such as prolonged treatments and recurrent events. Outcome 
differences were additionally described among all etiologic groups. Results: A total of 
225 events were diagnosed in 117 patients (corresponding to 0.96 events/patient-year). 
Infections were predominantly caused by Gram positive agents (47.6%), namely 
Staphylococcus aureus (18.2%) and Corynebacterium spp (15.6%). Reduced adequacy 
parameters were more often associated with Gram positive bacterial events than with 
Gram negative infections. However, similar outcomes were observed between both 
groups. Staphylococcus aureus infections associated to lower percentages of 
supplementation with vitamin D, lower levels of HDL cholesterol, preferentially occurred 
early after peritoneal dialysis initiation, required prolonged treatments and more 
frequently associated to tunnel infections and peritonitis. Conclusion: Exit-site infections 
in PD patients are still common events, related to substantial morbidity. Staphylococcus 
episodes represented, in our population, a subgroup of infections with a particular clinical 
profile and were associated with a significant clinical burden. 
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Resumo 
 
Introdução: As infeções do orifício de saída do cateter peritoneal constituem ainda um 
problema clínico relevante em diálise peritoneal. Apesar da epidemiologia associada a 
estas infeções já ter sido abordada em trabalhos prévios, os fatores de risco 
especificamente relacionados com infeções causadas por agentes Gram positivos e 
Gram negativos permanecem ainda por esclarecer. Objetivo: Avaliar retrospetivamente 
os fatores associados à presença e evolução das infeções do orifício de saída causadas 
por agentes Gram positivos e Gram negativos. Métodos: Incluíram-se todos os casos 
de infeção do orifício de saída do cateter peritoneal diagnosticados em doentes seguidos 
numa Unidade de Diálise Peritoneal do Hospital S.João entre 2011 e 2012. Os doentes 
com infeção Gram positivo e Gram negativo foram comparados relativamente a 
variáveis demográficas, clínicas e analíticas. A abordagem foi alargada ao estudo de 
infeções com etiologias específicas (Staphylococcus aureus e Pseudomonas 
aeruginosa) e evoluções distintas (tratamentos prolongados e eventos recorrentes). Foi 
registada e comparada a evolução clínica dos vários grupos etiológicos. Resultados: 
Diagnosticaram-se 225 eventos em 117 pacientes (0.96 eventos/paciente-ano). As 
infeções foram causadas predominantemente por agentes Gram positivos (47.6%), 
nomeadamente Staphylococcus aureus (18.2%) e Corynebacterium spp (15.6%). Os 
episódios causados por bactérias Gram positivas relacionaram-se com parâmetros de 
adequação dialítica inferiores aos observados nas infeções por bactérias Gram 
negativas. Contudo, a evolução clínica foi semelhante nestes dois grupos. As infeções 
por Staphylococcus aureus associaram-se a menor percentagem de doentes 
suplementados com vitamina D, a níveis inferiores de colesterol HDL, ocorreram 
precocemente após o início da diálise, implicaram tratamento antibiótico prolongado e 
resultaram mais frequentemente em infeções do túnel e peritonites. Conclusão: As 
infeções do orifício de saída em diálise peritoneal são um evento frequente, 
condicionando morbilidade significativa. Os episódios causados por Staphylococcus 
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aureus constituíram, na nossa população, um subgrupo de infeção com perfil clínico 
singular associado a elevada carga assistencial. 
 
Palavras-chave: Infeções do orifício de saída, Bactérias Gram-negativas, Bactérias 
Gram-positivas, Diálise peritoneal. 
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Introduction 
 
Peritoneal dialysis (PD) is an effective form of renal replacement therapy. Despite the 
improvements in PD technology, infection remains one of the most important preventable 
cause of morbidity and mortality, as well as of hospitalization, in patients undergoing 
dialysis (1). PD infections include exit-site infections (ESI), tunnel infections (TI) and 
peritonitis, this last one considered the main undesired complication of PD.  Despite 
numerous improvements in PD technique, exit-site care and infection prophylaxis, ESI 
are still clinically relevant since they are associated with prolonged antibiotic treatment, 
increased morbidity, catheter dysfunction, peritonitis and with PD discontinuation (2, 3). 
Overall, ESI are predominantly caused by Gram positive (G+) bacteria. Previous studies 
have shown that ESI and TI are most often caused by Staphylococcus aureus (S. 
aureus) (25-50%) followed by Pseudomonas aeruginosa (10-28%), both of which tend 
to recur and frequently lead to peritonitis (4). Other microorganisms that colonize the skin 
are also involved, such as Staphylococcus coagulase negative (10-35%) and 
Corynebacterium (2-9%)(5, 6).  Non-diphtheria Corynebacteria species are major agents 
of the normal flora of the skin and mucous membranes and are frequently discarded as 
contaminants. For this reason, Corynebacterium infection rates in PD are most probably 
underestimated in the literature. Nevertheless, they are considered pathogenic in high-
risk populations, such as immunocompromised individuals and patients with indwelling 
catheters and should not be undervalued in the context of peritoneal dialysis.  
In the most recent years the spectrum of bacteria causing infections in the PD population 
is changing, with a significant higher proportion of Gram negative (G-) agents. This is in 
part due to improvements made in connection systems, pre- and postoperative catheter 
care such as S. aureus prophylaxis, allowing an important reduction in the proportional 
incidence of PD infections caused by G+ bacteria. Additionally, it is well established that 
G- infections are associated with worse outcomes (7, 8).  
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Although detailed descriptions about microbiologic epidemiology associated to ESI are 
found in the literature, little is known about the risk factors associated to G- comparing 
to G+ infections. Here we report an observational study designed to examine if specific 
background parameters, such as demographic, clinical, analytical, pharmacological or 
PD-related factors are associated to ESI caused by G- versus G+ bacteria. This analysis 
is extended to specific ESI etiologies, such as S. aureus, other G+ bacteria or 
Pseudomonas aeruginosa. We also describe outcome differences among all etiologic 
groups. To go further, the same background parameters are also compared between 
groups of ESI with different outcomes, such as sequential infections, prolonged medical 
treatment, non-cured and recurrent ESI.  
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Subjects and Methods 
 
This study describes a retrospective and observational analysis of all ESI episodes 
occurring in a population of prevalent PD patients followed in a single unit in Portugal 
(Nephrology Department of Centro Hospitalar S. João), between 2011 and 2012. All 
patients had a double-cuffed Tenckhoff catheter implanted using standard surgical 
techniques and were submitted to antibiotic prophylaxis with 1 gram of intravenous 
cefazolin on the day of the PD catheter insertion. On average, 15 days after PD catheter 
implantation patients initiated intensive training sessions for PD technique-related issues 
and exit-site care. 
ESI were diagnosed whenever clinical signs of infection were detected, as indicated in 
the International Society of Peritoneal Dialysis (ISPD) Guidelines/Recommendations (9). 
Sequential infection was diagnosed when different microorganisms were culturally 
isolated from the same ESI episode in a different microbiological culture. TI diagnosis 
was made taking in consideration the presence of clinical signs such as erythema, 
edema or tenderness along the subcutaneous catheter pathway and/or ultrasound 
results identifying suspicious subcutaneous collections. Peritonitis was considered in the 
presence of two of the following three findings: abdominal pain, cloudy effluent with ≥50% 
polymorphonuclear cells or positive microbiological culture of the dialysate fluid. 
Data of ESI episodes were gathered from medical records for the following variables: (a) 
Demographic characteristics, such as age at the time of ESI diagnosis, gender, 
residence characteristics (city/rural), water supply (public network/well); (b) Previous 
comorbid diseases such as diabetes mellitus (DM), hypertension, cardiovascular 
disease (this group included cardiac, cerebrovascular and peripheral vascular disease), 
chronic kidney disease (CKD) etiology and duration, previous infectious episodes (ESI, 
peritonitis, respiratory infections or other) on the last 3 months and presence of 
constipation; (c) Analytical profile, including hemoglobin, albumin, A1c hemoglobin and 
lipid profile, calcium, phosphorus, pH, bicarbonate, B-type natriuretic peptide, 
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sedimentation rate and C reactive protein; (d) Pharmacological profile, including previous 
antibiotherapy in the last 3 months, immunossupressors, anti-platelet agents, anti-
coagulants and vitamin D supplementation; (e) Characterization of PD technique, 
including PD modality, degree of residual renal function, diuresis, weekly creatinine 
clearance, weekly Kt/V and peritoneal transport status defined by the 4h creatinine D/P 
obtained by the peritoneal equilibration test; (f) ESI episode characterization, namely the 
presence of serous-hematic or purulent drainage, microbial culture result, antibiotic 
treatment duration and ESI outcome (TI, peritonitis, ESI cure, external cuff removal, 
catheter substitution or removal, hemodialysis transfer).  
Ambiguous exit-sites were kept under close clinical surveillance with topical antibiotic, 
saline soak or silver nitrate solution and were treated with systemic oral antibiotic if no 
improvement was observed after approximately 1 week. Empiric treatment was usually 
initiated with cotrimoxazole, normally for 2 weeks. Once the microbial culture report was 
available, the patient was switched to a specific antibiotic agent directed by the 
susceptibility profile (9).  
Prophylaxis of fungal peritonitis was undertaken with oral fluconazole in cases of 
prolonged antibiotic therapy (treatment duration superior to 1 month). If extended 
appropriate antibiotic treatment failed to resolve the infection, the patient was 
successively oriented for one of the following procedures: external cuff removal, catheter 
substitution or removal and hemodialysis transfer. 
Statistical tests were applied to several sets of samples of ESI with different microbial 
etiologies, such as G- vs. G+ bacteria, S. aureus vs. Pseudomonas aeruginosa, S. 
aureus vs. other G+ bacteria or S. aureus vs. non-S.aureus bacteria. The same tests 
were used to compare samples related to different episode developments, such as those 
with vs. without sequential infections, those requiring >30 days vs. ≤30 days of medical 
treatment, non-cured vs. cured episodes and recurrent vs. single ESI episodes. 
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Statistical Analysis 
The statistical analysis was performed using SPSS version 21 for Windows. Univariate 
analysis was conducted to identify potential correlations between variables and ESI. The 
association between two categorical variables was evaluated by Chi square test or 
Fisher’s exact test, as appropriate. For continuous variables the Student’s t-test (for 
normally distributed variables) or the non-parametric Mann-Whitney were used. 
Variables were considered to have statistically significant association with ESI if the p 
value was ≤ 0.050. 
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Results 
 
Characterization of the population studied 
Throughout the two-year period, a total of 225 ESI events were diagnosed, occurring in 
117 patients. The follow-up of the group of patients studied represented a total of 246.15 
patient-dialysis years of observation, resulting in an incidence of ESI during the period 
analysed of 0.91 ESI/patient-year. Table I shows the demographic and epidemiological 
data associated with the 117 patient sample. The population evaluated had median age 
of 47 years and was constituted by 65.8% of males. One hundred and five patients 
(89.7%) suffered from at least one comorbid disease (hypertension, DM or 
cardiovascular disease). Chronic kidney disease was most frequently caused by 
glomerulonephritis (17.9%) and diabetes mellitus (13.7%). The frequency of patients 
experiencing a single ESI (48.7%) was similar to the frequency of patients having 
multiple ESI (51.3%) during the two-year period. A median of 2 events per patient was 
registered (range: 1-9).  
 
Characterization of the ESI sample 
Among the total of 225 ESI analysed, the median age at the moment of diagnosis was 
48 years (range: 19-84 years). PD duration had a median of 1 year (range: 0-6), 71.1% 
were on CAPD and 24.0% on APD (Table I) and all patients used standard bicarbonate 
based PD solutions with 1.25mmol/L of calcium. Preceding infections were present in 
the last 3 months in 41.8% of the episodes, of which 28.9% were due to ESI. 
Concerning the relevant pharmacological profile, supplementation with vitamin D and 
immunossupressive therapy were prescribed in 54.7% and 7.6% of the cases, 
respectively. In 41.3% of the current ESI episodes, previous antibiotic treatment was 
prescribed for an infectious episode in the preceding 3 months. 
Microbiologic cultures were positive in 66.7% of the ESI episodes, 23.1% resulted in non-
specific bacterial growth and 4.4% were negative. In 64.0% of the cases the isolates 
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were purely bacterial and 2.7% were due to Candida parapsilosis, the only fungal agent 
isolated (Table II). G+ organisms were isolated in 47.6% of the cases and G- agents in 
21.3%. S. aureus and Corynebacterium spp were the most commonly isolated bacteria 
(47.6% and 18.2%), followed by Pseudomonas aeruginosa (10.2%). Co-infections, i.e. 
simultaneous isolation with more than one agent, were observed in a small number of 
episodes (4.9%) and frequently due to growth of G+ bacterial species (2.7%), followed 
by G- bacteria (1.3%) and finally by a mixture of both (0.9%). No more than two species 
were isolated in each co-infection. Moreover, 16.4% of the events complicated with 
sequential infections a few days after diagnosis, i.e. new microbial agents isolated during 
a single ESI episode. Of these superimposed infections, G+ microorganisms were more 
frequently isolated (17.8% vs. 2.2% for G- bacteria), with only three cases (1.3%) of 
Candida Parapsilosis infection. These sequential infections were more often caused by 
Staphylococcus coagulase negative and Corynebacterium spp (9.8% and 4.4%, 
respectively).  
Bacterial ESI were, in most cases, successfully controlled (85.0%) with antibiotic therapy 
for a median duration of 33 days (range: 13-199). Fungal infections were medically 
treated in 66.7% of the cases with anti-fungal drugs for a median duration of 74.0 days 
(range: 23-86). Patients with non-cured ESI were orderly proposed for external cuff 
removal (3.6%), catheter substitution/removal (9.3%) and hemodialysis transfer (0.9%), 
whenever indicated. Tunnel infections and peritonitis were reported in 12.9% and 3.6% 
of the cases, respectively. 
 
Association of specific characteristics of the population according to ESI 
etiologies and outcomes 
 
Comparison of specific characteristics of the population studied according to distinct ESI 
samples are described in Table III, IV and V. 
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Demographic, clinical and pharmacological parameters 
Statistical tests applied to several sets of samples of ESI with different microbial 
etiologies showed no association with age, environment (city or rural) or type of water 
supply. However, a strong association with gender was observed among specific groups. 
S. aureus ESI were more prevalent in men (87.8%) and Pseudomonas in women 
(56.5%) (p<0.001). Similar results were found when comparing S. aureus events with 
other G+ bacterial ESI (p=0.003) or with non-S.aureus bacterial events (p=0.001). No 
obvious demographic differences were observed in the comparison of samples with 
different outcomes (with vs. without sequential infections, >30 days vs. ≤30 days of 
medical treatment, non-cured vs. cured episodes and recurrent vs. single ESI episodes).  
Clinical parameters, such as DM, hypertension, cardiovascular disease, smoking or CKD 
etiology, previous hemodialysis treatment, previous renal transplant or constipation were 
not associated to specific ESI etiologies or outcomes. Considering the pharmacological 
profile, S. aureus infections occurred less frequently in patients on vitamin D 
supplementation, comparing to non-S. aureus events (36.6% vs. 57.7%, p=0.022).  
 
Biochemical parameters 
Considering the analytical evaluation, significantly reduced levels of HDL cholesterol 
were reported in G+ bacterial ESI when comparing to infections caused by G- bacteria 
(45.0 vs. 49.0 mg/dL, p=0.039). These results were reproduced when specifically 
considering S. aureus vs. Pseudomonas aeruginosa events (41.7 vs. 50.6 mg/dL, 
p=0.003), S. aureus vs. other G+ bacterial infections (41.7 vs. 49.2, p=0.007) and S. 
aureus vs. non-S. aureus events (41.7 vs. 50.6, p=0.003). Lower levels of HDL were also 
significantly associated to ESI with sequential infections (42.5 vs. 46.0, p=0.030). 
Additionally, the levels of triglycerides were found to be higher in ESI with extended 
antibiotic treatment (158.0 vs. 133.0 mg/dL, p=0.047). 
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PD-related parameters 
Considering PD therapy duration, S. aureus events occurred earlier after PD initiation 
(before completing a year of PD) when compared to other G+ ESI (p=0.002) or non-S. 
aureus infections (p=0.004). No correlations were reported between PD modalities 
(CAPD or APD) and specific ESI etiologies or outcomes. 
G+ bacterial infections were associated to decreased levels of total Kt/V when compared 
to G- events (1.80 vs. 2.20, p=0.022). We also found lower levels of total Kt/V associated 
to S. aureus ESI in comparison to infections caused by Pseudomonas aeruginosa (1.68 
vs. 2.27, p<0.001), other G+ bacterial ESI (1.70 vs. 2.00, p<0.001) or by non-S. aureus 
(1.70 vs. 2.10, p<0.001). Reduced levels of total creatinine clearance per week were 
additionally correlated with S. aureus infections in comparison to other G+ bacterial ESI 
(75.95 vs. 111.30 L/week, p=0.003) as between S. aureus vs. non-S. aureus (75.95 vs. 
92.96 L/week, p=0.017). Moreover, a significant statistical difference of the total renal 
clearance was reported among S. aureus vs. other G+ bacterial ESI (2.40 vs. 4.99 
ml/min, p=0.031). Statistical tests applied to PD-parameters comparing single vs. 
recurrent ESI also revealed lower levels of diuresis in the latter group (1175 vs. 950ml, 
p=0.023). 
 
Previous infections/ antibiotic therapies 
S. aureus events were not related to the presence of previous infections or ESI when 
considered individually. However, when present, previous ESI were longer than those 
preceding other G+ bacteria events (65.0 vs. 28.5 days, p=0.021) or non-S. aureus ESI 
(65.0 vs. 29.5 days, p=0.009). Similar findings were observed when analysing episodes 
treated for more than 30 days in comparison to those treated in a shorter period of time 
(42.0 vs. 23.0 days, p=0.001). Furthermore, when compared to the group of cured 
events, non-cured ESI were associated with reduced intervals between the previous 
infection and the current episode (19.5 vs. 36.0 days, p=0.026). 
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Although, S. aureus episodes were not related to previous ESI, considering the sample 
of all preceding episodes, this was not what we have observed when specifically 
considering previous S. aureus events. In fact, current S. aureus infections strongly 
correlated with preceding infections by the same agent (58.3% vs. 10.0%, p=0.006). 
Despite the fact that S. aureus ESI were not related to previous antibiotic therapy in the 
last 3 months, when present these were more frequently prolonged treatments requiring 
different antibiotic agents when comparing to the group of other G+ bacterial ESI (55.2 
vs. 29.0 days, p=0.014; 3 vs. 1 antibiotic classes, p=0.005) and non-S. aureus ESI (58.5 
vs. 25.5 days, p=0.017; 3 vs. 2 antibiotic classes, p=0.008). Similar results were obtained 
when comparing ESI treated for more than 30 days vs. those treated in a shorter period 
of time (37.0 vs. 21.0 days, p=0.005; 2.5 vs. 1 antibiotic classes, p=0.001) and non-cured 
vs. cured ESI (37.0 vs. 25.0 days, p=0.029; 3 vs. 2 antibiotic classes). Non-cured events 
also were significantly associated with shorter periods of time between the last antibiotic 
therapy and the actual event (18.0 vs. 40.0 days, p=0.006).  
 
ESI clinical presentation 
Overlapping clinical presentations (serous-hematic/purulent exsudates) were observed 
among different ESI etiologies. An exception was observed for S. aureus infections, 
which more frequently associated to serous-hematic exsudates than Pseudomonas 
aeruginosa ESI, despite the fact that no recognisable differences were documented 
among these microbial agents regarding the presence of purulent drainage. No specific 
clinical presentations associated to the presence of sequential infections, extended 
treatment events, non-cured or recurrent ESI. 
 
Outcome 
Although no statistical significant difference was demonstrated regarding treatment 
duration between G+ vs. G- infections, specific ESI etiologies, such as S. aureus 
infections were consistently related to prolonged treatments when compared to 
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Pseudomonas aeruginosa events (49.0 vs. 32.0 days, p=0.046), to other G+ bacterial 
infections (49.0 vs. 29.0 days, p=0.001) and to non-S. aureus events (49.0 vs. 31.0 days, 
p=0.001). Longer medical treatments were also required in ESI with sequential infections 
(67.5 vs. 27.5 days, p<0.001) and in those considered medically non-cured (51.5 vs. 
29.0, p<0.001). G- ESI medical treatments required more antibiotic agents than G+ 
infections (3 vs. 2, p=0.029). Similar results were found among S. aureus vs. other G+ 
infections (3 vs. 2, p=0.001), S. aureus vs. non-S. aureus events (3 vs. 2, p=0.019), ESI 
with vs. without sequential infections (3 vs. 1, p<0.001) and non-cured vs. cured events 
(3 vs. 2, p<0.001). 
No recognisable differences on ESI outcomes (such as TI, peritonitis, ESI cure, external 
cuff removal, catheter substitution/removal or HD transfer) were observed between ESI 
caused by G+ vs. G- bacteria, S. aureus vs. Pseudomonas aeruginosa or S. aureus vs. 
other G+ bacteria. A difference was however reported between S. aureus and the 
broader group of non-S. aureus infections, the former more frequently associated to TI 
(66.7% vs. 37.0%, p=0.050) and subsequent peritonitis events (9.8% vs. 1.0% ESI, 
p=0.023). Moreover, although a low frequency of peritonitis was reported in this study 
(3.6%), it strongly associated with the presence of TI (13.8% with TI vs. 0.0% without TI, 
p=0.020) and to the need for surgical catheter substitution/removal (14.3% with surgical 
intervention vs. 2.5% without surgical intervention, p=0.029). Accordingly, non-cured ESI 
strongly correlated to TI (84.6% vs. 29.0%, p<0.001). 
Lower rates of exit-site cure and higher rates of external cuff removal were observed in 
the group of ESI with sequential infections (73.0% vs. 89.7%, p=0.013 for exit-site cure; 
10.8% vs. 2.3%, p=0.033 for external cuff removal) and in episodes treated for more than 
30 days (83.3% vs. 96.2%, p=0.002 for exit-site cure; 6.3% vs. 0.0%, p=0.011 for 
external cuff removal). Finally, recurrent ESI apparently did not correlated to worse 
outcomes when compared to single events.  
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Fungal infections 
Although rare, fungal infections were still characterized. In order to increase the number 
of cases, fungal episodes included those with fungal isolates in the initial diagnosis and 
in subsequent sequential infections, making a total of 9 events (4.0%). Fungal infections 
were associated with a higher frequency of immunossupressive therapy (33.3% vs. 
8.1%, p=0.043) and to higher sedimentation rate values (82.0 vs. 58.3 mm/h, p=0.031). 
Patients with these infections were on PD for a longer period of time (2.5 vs. 1.0 year in 
non-fungal ESI, p=0.008) and showed decreased adequacy PD parameters (diuresis, 
total renal clearance and total creatinine clearance). Moreover, these episodes were 
correlated to prolonged antibiotic treatment (74.0 vs. 35.0 days, p=0.005) and to higher 
rates of peritonitis (33.3% vs. 2.8%, p=0.005). 
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Discussion 
 
In our PD population, ESI were a relatively common event, occurring with an incidence 
of 0.91 ESI/patient-year. ESI were mostly caused by G+ agents, of which S. aureus was 
the most commonly isolated microorganism, followed by Corynebacterium spp. 
Staphylococcus aureus infections occurred preferentially early after peritoneal dialysis 
initiation, required prolonged treatment periods, were more frequently associated to 
tunnel infections and peritonitis and represented, in our population, the subgroup of 
infections with the most particular clinical profile. 
 
Agents and Incidence Rates  
In our population we have documented an ESI incidence of 0.91 episodes/patient-year. 
Previous studies have demonstrated that ESI rates can vary from 0.05 to 1.02 
episodes/patient-year (10-12). Some authors suggested that this apparent discrepancy 
are more likely related to differences in the diagnostic criteria used rather than to the real 
impact of prevention measures, namely exit-site management, S. aureus infection 
prophylaxis or patient training (13). Indeed, ESI diagnosis is not always a simple and 
straightforward task. Several definitions of ESI have been proposed during the past 
decades, and the clinical presentations from uninfected to infected exit-sites are wide 
and diverse. Different skin adaptive responses to the peritoneal dialysis catheter can 
also contribute to this heterogeneity (14). Moreover, some authors establish the 
diagnosis of ESI on the basis of a positive microbiologic culture, which does not 
necessarily correlate to the presence of infection, but may represent skin colonization 
instead. On the other hand, negative cultures may also be associated to ESI. This 
heterogeneity was probably the main reason why the ISPD 2010 
Guidelines/Recommendations recommended the diagnosis of ESI mainly based on 
clinical findings and not on microbiological results (9). Taken together, all these 
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limitations pose several problems in the direct comparison of ESI incidences among 
different PD Units.  
 
In our study, ESI were mostly caused by G+ agents (47.6%) in comparison to G- bacteria 
(21.3%). This result is corroborated by similar reports in the literature, which 
consensually document higher frequencies of G+ infections (11, 12, 15). Indeed, many 
of these G+ microorganisms are normal colonizing agents of the skin flora in healthy 
individuals, but may become pathogenic in immunosuppressive states like end-stage 
renal disease (ESRD). Despite the improvements observed in PD technology and in 
hygiene measures, the manipulation of the catheter in PD patients is still associated with 
a high risk of skin and oral cavity microbiota migration and, consequently, G+ infections. 
In the last years, the introduction of prophylactic measures has enabled PD programs to 
reduce the incidence of G+ infections, but have also led to a proportional increase of G- 
events relatively to all PD infections (7, 8, 16-18). G- ESI are thought to occur due to 
faecal contamination and poor hand washing techniques during the peritoneal exchange 
(16). Although, less frequent than G+ infections, G- bacteria are known for their 
increased virulence and worse outcomes (7, 19, 20), and they deserve careful attention 
in the context of exit-site management.  
Regarding specific etiologic agents, S. aureus was the primary cause of ESI in our study 
(18.2%). Although not always pathogenic, S. aureus may be responsible for severe 
infections, especially in immunocompromised individuals. Several reports have 
confirmed that S. aureus prophylaxis measures with mupirocin significantly reduce the 
incidence of ESI and peritonitis caused by this microorganism in PD patients (15, 21, 
22). Accordingly, these procedures have been recommended by the ISPD. Despite these 
efforts, previous studies have demonstrated that S. aureus still constitutes one of the 
main causes of ESI in PD, with rates varying from 19.7 to 29% (9, 11, 15, 23).  
In our population Corynebacterium spp infections were the second most frequent cause 
of ESI, accounting for 15.6% of all episodes. Previous studies focusing on 
20 
 
Corynebacterium ESI showed frequencies of approximately 9% (5), somewhat inferior 
to those observed in our patients. Non-diphtheria Corynebacteria species are major 
agents of the normal flora of the skin and mucous membranes, therefore commonly 
dismissed as contaminants. Due to the relatively high incidence of these infections and 
to the significant clinical implications for PD patients when they occur, our study supports 
the importance of a close interaction with the local microbiology lab, aiming to optimize 
the identification of these microorganisms in the context of ESI. 
In the present study, Pseudomonas aeruginosa ESI were reported in 10.2% of the cases. 
After S. aureus, Pseudomonas aeruginosa is usually described as the most frequent 
cause of ESI, with rates varying from 8 to 14.4% (11, 12, 15, 24). Some authors have 
recomended a daily basis application of a gentamicin cream to the exit-site to prevent 
both Pseudomonas aeruginosa and S. aureus infections (25). Despite this efforts, 
infections by Pseudomonas are still difficult to prevent. These infections are usually 
serious, particularly difficult to treat and frequently lead to peritonitis and thus should be 
managed aggressively.  
 
Association of specific characteristics of the population according to ESI 
etiologies and outcomes 
 
Clinical and pharmacological parameters 
No significant association was observed between DM (including degree of glicemic 
control) or other comorbidities (hypertension or cardiovascular disease) and G+ or G- 
infections. Similar results were documented when considering specific ESI etiologies or 
outcomes. Previous studies have demonstrated that DM is associated with reduced 
innate and adaptive immune responses, increasing the susceptibility to infections (26-
28). Furthermore, especially if complicated by poor glicemic control, DM increases the 
susceptibility to infection among patients in PD (12).  In fact, poor glycemic control was 
considered a consistent predictor of subsequent risk for TI and ESI, but not for peritoneal 
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infection (29). In our population we have documented a low mean value of HbA1c (5.7%), 
suggesting a good glicemic control of our diabetic population. Additionally, diabetics 
accounted for less than 30% of the population studied. These facts, taken together, may 
help to explain why the expected association between diabetes and ESI episodes was 
not documented.  
We have not identified a relation between vitamin D supplementation and type of ESI 
episodes, namely G+ or G- ESI. However, we did demonstrate that S. aureus infections 
occurred less frequently in cases associated with vitamin D supplementation, comparing 
to the sample of non-S. aureus events. An increasing number of studies are pointing to 
a crucial role of vitamin D in immune responses. Indeed, nearly all tissues in the body 
have receptors for the active form of vitamin D and this compound has been shown to 
have a pivotal function in the modulation of monocyte/macrophage response to infection 
and in several cellular immune mechanisms as well. Additionally, an anti-inflammatory 
role of vitamin D has been documented in several bacterial infections (30, 31). Recent 
publications have demonstrated an association between the treatment with oral vitamin 
D and a decreased risk of peritonitis in patients undergoing PD (32, 33). However, the 
role of vitamin D in other PD related infections, namely in ESI, is still very poorly 
understood. Despite the fact that serum vitamin D levels were not evaluated in our 
population of patients, our results may point to an eventual contribution of vitamin D oral 
supplementation in the protective immune response against S. aureus ESI. Further 
studies focusing on this subject are obviously needed. 
 
Analytical parameters 
We found no association between CRP, a well recognized inflammatory parameter, and 
G+ or G- infections. This was also documented when considering specific types of 
bacterial infections or episodes with distinct clinical outcomes. Chronic inflammation and 
concomitant increased levels of CRP are normally present in ESRD patients including 
those on PD (34, 35).  Several studies have previously evaluated the relation of CRP 
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levels with the presence of PD-related infections, demonstrating an association of higher 
CRP levels with poor peritonitis outcomes. (36). The association of CRP with the 
presence of ESI has not yet been explored. ESI are usually controlled events, limited to 
the superficial tissues, what could help to explain the absence of relation between CRP 
levels and ESI incidence and outcome. Thus, it seems reasonable to suggest that CRP 
should not be used as a clinical instrument to identify the presence or predict the etiology 
or clinical behaviour of an ESI episode.  
No obvious association was also documented between the levels of serum albumin and 
G+ or G- episodes. Albumin values were also similar between ESI samples with distinct 
etiologies and clinical outcomes. Low levels of serum albumin have been associated with 
increased mortality in the context of PD (37).  The presence of comorbidities, possible 
ongoing losses of protein into the dialysate fluid, co-existing chronic inflammation and 
the volume status all may contribute to hypoalbuminemia in PD patients. Previous 
studies have demonstrated that initial serum albumin was an independent risk factor for 
peritonitis in PD patients (38). No relevant information about the relation between 
hypoalbuminemia and ESI episodes is reported in the literature. In PD patients ESI may 
be, therefore, mainly related to local risk factors and technical issues and not reflect the 
systemic predisposition to infection. Further studies on this matter, namely directed to 
the immune response characterization of patients with recurrent ESI, would be 
necessary.  
In this study, G+ ESI were predominantly associated with lower levels of serum HDL 
cholesterol when compared to infections caused by G- agents. Further analysis revealed 
that, within the G+ episodes, these low levels of HDL were predominantly associated 
with S. aureus infections.  Similar results were observed when considering ESI with 
sequential infections, which commonly required prolonged treatments and less 
frequently evolved to cure. Numerous studies have demonstrated that infection and 
inflammation are accompanied by cytokine-induced alterations in lipid and lipoprotein 
metabolism, decreasing both LDL and HDL-cholesterol, by mechanisms not yet fully 
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understood. Conversely, anti-inflammatory effects of HDL have been demonstrated both 
in in vitro and in vivo studies (39). HDL binds microorganisms or compounds derived 
from microbial agents (e.g. lipopolysaccharide from G-, lipoteichoic acid from G+ 
bacteria), thus blocking the activation of cytokine production by competing successfully 
with cellular receptors for microbial components. (39). Our observations suggest that low 
HDL may predispose the host to the virulent effects of specific microorganisms, like S. 
aureus and increase the risk of infection by this agent. The validity of this association 
and the mechanisms underlying this relation need to be further clarified. 
 
PD-parameters 
When considering the broader groups of G+ and G- episodes, no significant differences 
were reported concerning the elapsed time from PD initiation to the ESI diagnosis. On 
the contrary, specific S. aureus events preferentially occurred before completing 1 year 
of PD therapy. We thus suggest that, despite the worse clinical outcomes, S. aureus ESI 
do not necessarily correlate with long-standing PD treatments or its related 
complications. Several co-existing factors may contribute to this finding. It is well 
established that patient education and training positively influence the risk of PD 
infections (40, 41). Inadequate hygiene habits associated with technical inexperience in 
the early stages of PD might predispose patients to specific ESI etiologies, such as those 
caused by S. aureus. Moreover, the concomitant incomplete healing of the exit-site in 
the first weeks of PD may additionally contribute to this type of infection. We, thus 
reinforce the need to ensure early management of the exit-site, such as intensive training 
in the basic procedures for exit-site care and implementation of mupirocin prophylaxis 
soon after PD-catheter insertion.   
In this study, specific PD modalities were not associated with any of the considered ESI 
agents. Meta-analysis studies have demonstrated that patients on APD had lower rates 
of peritonitis, but similar rates of ESI and TI where observed when comparing PD 
modalities (42). This may be explained by the fact that ESI is predominantly related to 
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the local skin care technique and not dependent on the connection procedure and 
reinforces the need to address prophylactic measures for ESI and peritonitis 
differentially.  
In our sample, G+ ESI episodes were more often associated with reduced adequacy 
values than G- infections. Infections remain the major cause of morbidity and mortality 
in uremic patients, specially in those undergoing dialysis. In CKD patients the infectious 
risk is enhanced by, among other factors, uremic toxic retention and malnutrition. It is 
therefore reasonable to assume that efficiently dialysed patients may be more capable 
of deviating the immune response from a suppressive state towards a stronger reaction 
against infection. G+ bacteria are commonly present in the skin flora of healthy subjects 
and are generally less virulent than G- microorganisms. As a consequence of these 
weaker virulence mechanisms, G+ infections may be more frequently associated with 
poorer dialysis efficiency, which presumably correspond in PD patients to the worse 
scenarios of immunossupression.  
A significant statistical difference in the levels of diuresis between single ESI events and 
recurrent infections was documented in our study. In fact, ESI episodes occurring more 
than once correlated with lower diuresis. The volume of diuresis usually reflects the 
residual renal function (RRF), which is characteristically preserved in PD patients. The 
loss of RRF has been demonstrated to contribute to anaemia (43), inflammation (44), 
malnutrition (45) and to the increase of mortality rates (46). Though previous studies 
have demonstrated that RRF is an independent risk factor for PD peritonitis, studies 
reporting the association of RRF with the rates of ESI are still missing in the literature 
(47). Although we cannot truly evaluate the effect of RRF in the rates of ESI, our results 
suggest that RRF may play a protective role against the relapse of ESI in patients 
undergoing PD. 
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Previous infections/ antibiotic therapies 
We have not observed a relation between the existence of preceding infections (including 
ESI) or antibiotic therapies and current episodes caused by of G+ and G- bacteria. 
However, we could document that current S. aureus infections strongly correlated with 
preceding infections caused by the same agent. Studies in the literature have 
documented recurrent S. aureus infections in nasal carriers and in intermittent nasal 
carriers (48). In the case of intermittent carriers, S. aureus nasal screening may be 
associated with a false negative result. It is well established that S. aureus nasal carriers 
exhibit higher incidences of ESI, TI and peritonitis events (49). It is thus possible that 
recurrent S. aureus infections may associate with misdiagnosed carriers or intermittent 
carriers in our population. Alternatively, one may also consider re-infection of the exit-
site by silent S. aureus bacteria remaining in the catheter from a previous clinically 
healed ESI. However, some studies have documented recurrent S. aureus events 
despite the removal of the infected catheter (50).  This observation, thus, supports the 
idea of an intrinsic predisposition of some individuals to S. aureus infections. 
Moreover, although we could not associate the presence of previous ESI/antibiotic 
therapies with current episodes requiring prolonged treatments (more than 30 days), if 
present, those preceding infections most frequently had similar durations. As suggested 
above, these cases may reflect a state of intrinsic susceptibility to infection and/or an 
immunossupressive basal profile that may predispose individuals to a weaker response 
to therapy in the presence of recurrent infections. 
 
Outcome 
Regarding ESI medical treatment, in our study we have documented similar antibiotic 
therapy durations and outcomes between G+ and G- infections, although the latter 
frequently required more than one class of antibiotic agent. Descriptions in the literature 
have specifically emphasized outcome differences between G+ and G- peritonitis. In fact, 
peritonitis caused by G- bacteria has been associated with more hospital admissions, 
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catheter dysfunction episodes and PD discontinuation (7, 19, 20). In contrast to 
peritoneal infection outcomes, we have demonstrated that ESI caused by G- or G+ 
agents are equally likely to evolve to cure. Unlike peritonitis, which may lead to exuberant 
systemic responses that may contribute to a high morbidity and mortality, ESI are usually 
locally circumscribed events, confined to the superficial tissues. Accordingly, it is 
reasonable to speculate that despite the increased virulence mechanisms associated to 
G- bacteria, appropriate antibiotic therapies and exit-site care measures are capable of 
successfully restricting the infection to the boundary tissues, eventually leading to cure. 
Finally, we have demonstrated that S. aureus infections required extended antibiotic 
therapies and were more frequently associated to TI and peritonitis. S. aureus is 
responsible for severe infections in immunocompromised individuals, as those with 
ESRD. In the context of PD, it is considered one of the most serious and common exit-
sit pathogens, since it is frequently associated to catheter-related infections, severe 
peritonitis and need for catheter removal (9, 51, 52). Dissemination to the peritoneal 
cavity frequently occurs through the catheter and is probably a more relevant route of 
infection than hand contamination. S. aureus nasal carriage constitutes a major risk 
factor for ESI, tunnel infection, peritonitis and catheter loss. Although the emergence of 
mupirocin-resistant S. aureus in PD patients has been documented (53), ISPD continues 
to recommend the use of mupirocin prophylaxis, provided that periodic surveillance is 
not neglected. The significant incidence of these infections in our population associated 
to a poorer clinical outcome and aggressive therapeutic regimens, all stress the need for 
reinforcing prevention measures against S. aureus infections, such as patient education, 
careful exit-site care management and S. aureus prophylaxis, without underestimating 
of course the possible emergence of antibiotic-resistant strains.    
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To the best of our knowledge this is the first report thoroughly describing factors 
associated with different ESI etiologies and distinct clinical outcomes. However, our 
study has some limitations, mainly related to its retrospective nature, and further 
prospective studies are needed to support our results. 
In summary, although no significant differences were documented regarding the clinical 
outcome of G+ and G- ESI, we could identify some differences in these two types of 
infections. Lower HDL serum levels and reduced PD adequacy values were documented 
in patients with G+ events suggesting, as previously described in other clinical settings, 
a potential contributory role of HDL and dialysis efficacy to the regulation of the immune 
response of the patient undergoing PD. Moreover, we could find in our population that 
S. aureus infections were strongly correlated with worse outcomes and aggressive 
therapeutic approaches, supporting the idea that, despite all the improvements in PD 
technology and infection control measures, S. aureus ESI still represents a significant 
clinical burden for patients treated with PD. 
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 TABLE I: Characterization of the patient population 
Demographic & Clinical profile  
Gendera   
Male 77 (65.8%) 
Environmenta  
City 39 (33.3%) 
Rural 40 (34.2%) 
Water Supplya   
Public Network 63 (53.8%) 
Well 26 (22.2%) 
Comorbid Diseasesa 105 (89.7%) 
Diabetes mellitus 34 (29.1%) 
Type 2  23 (19.7%) 
Duration (years) 19.9 ± 9.9 
Hypertension 103 (88%) 
Duration (years) 11.0 (0-45) 
Cardiovascular Disease 39 (33.3%) 
Duration (years) 7.0 (0-28) 
Smokinga  22 (18.8%) 
Chronic Kidney Disease (CKD) a  
Etiology  
Diabetes mellitus 16 (13.7%) 
Hypertension 5 (4.3%) 
Glomerulonephritis 21 (17.9%) 
Polycystic Renal Disease 4 (3.4%) 
Chronic Pyelonephritis 4 (3.4%) 
Obstructive CKD 6 (5.1%) 
Unknown 17 (14.5%) 
Other 27 (23.1%) 
Duration (years) 7.0 (0-32) 
Previous Infectionsb  94 (41.8%) 
ESI  65 (28.9%) 
Peritonitis 15 (6.7%) 
Respiratory infections 9 (4.0%) 
Other 12 (5.3%) 
Duration (days) 28.0 (4-199) 
Days to event 35.0 (3-98) 
Pharmacologic profileb   
Anti-platelet agents 71 (31.6%) 
Warfarin 20 (8.9%) 
Immunossupressors  17 (7.6%) 
Vitamin D 123 (54.7%) 
Previous antibiotic treatment 93 (41.3%) 
Duration (days) 26.0 (5-119) 
Days to event 35.0 (0-133) 
Biochemical profileb   
Hemoglobin (g/dl)  11.4 ± 1.9 
Leukocytes(nºx109/L) 7.4 (3.47-52) 
Sedimentation Speed (mm/h) 61.2 ± 28.2 
Albumin (g/L)  37.5 (22.1-71.6) 
Alkaline Phosphatase (U/L)  110 (44-483) 
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Total Cholesterol (mg/dl)  176.0 ± 38.7 
HDL-Cholesterol (mg/dl)  45 (24-105) 
LDL-Cholesterol (mg/dl)  95.8 ± 29.4 
Triglycerides (mg/dl)  146 (41-598) 
HbA1C (%)  5.6 (4.2-9.4) 
Urea (mg/dl) 129.0 ± 37.3 
Creatinin (mg/dl) 8.1 (2.0-17.8) 
Calcium (mg/dl)  4.4 (2.1-10.0) 
Phosphorus (mg/dl)  4.8 (1.9-11.0) 
C-reactive protein (mg/L)  3.9 (2.0-187.3) 
pH  7.321 (7.143-7.485) 
Bicarbonate (mmol/L) 29.4 (18.1-36.3) 
Brain Natriuretic Peptide (pg/ml)  93.4 (10.0-4574.8) 
PD-parametersb  
PD modality   
CAPD 160 (71.1%) 
APD  54 (24.0%) 
PD duration (years) 1.0 (0-6) 
Adequacy parameters   
Total Renal Clearance (ml/min)  3.56 (0.00-20.68) 
Diuresis (ml)  1000 (0-3950) 
Total weekly Kt/V  2.00 (0.40-6.40) 
Total Clearance (L/week)  88.83 (17.92-423.29) 
D/P Cr (mg/dl)  0.78 (0.19-1.06) 
Results are expressed in: frequency (percentage); median (range); mean ± standard deviation. 
a Constant parameters among ESI. Values relative to the sample of patients (n=117) 
b Variable parameters among ESI. Median or average values are displayed accordingly, relative 
to all ESI episodes (n=225).               
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TABLE II: Microorganisms isolated from ESI and 
sequential infections  (n=225) 
Bacterial ESI  144 (64.0%) 
Gram positive 107 (47.6%) 
Staphylococcus aureus 41 (18.2%) 
Corynebacterium spp 35 (15.6%) 
Staphylococcus coagulase negative 16 (7.1%) 
Streptococcus spp 2 (0.9%) 
Other 13 (5.8%) 
Gram negative 48 (21.3%) 
Pseudomonas aeruginosa 23 (10.2%) 
Enterobacteriaceae 20 (8.9%) 
Other 5 (2.2%) 
Fungal ESI  6 (2.7%) 
Candida parapsilosis 6 (2.7%) 
ESI co-infection  11 (4.9%) 
Gram positive 6 (2.7%) 
Gram negative 3 (1.3%) 
Gram positive & Gram negative 2 (0.9%) 
Sequential infections 37 (16.4%) 
Nº agents isolated 1 (1-3) 
Bacterial sequential infections 45 (20.0%) 
Gram positive 40 (17.8%) 
Staphylococcus aureus 2 (0.9%) 
Corynebacterium spp 10 (4.4%) 
Staphylococcus coagulase negative 22 (9.8%) 
Streptococcus spp 1 (0.4%) 
Other 5 (2.2%) 
Gram negative 5 (2.2%) 
Pseudomonas aeruginosa 2 (0.9%) 
Enterobacteriaceae 2 (0.9%) 
Other 1 (0.4%) 
Fungal Sequential infections 3 (1.3%) 
Candida parapsilosis 3 (1.3%) 
Total fungal isolations (ESI & Sequential infection) 9 (4.0%) 
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Table III: Comparison of patient characteristics between ESI 
caused by Gram positive and Gram negative bacteria 
Patient variable Gram + ESI Gram - ESI p 
Previous infections    
Previous Infections  42 (42.4%) 16 (38.1%) 0.633b 
Duration (days) 47.0 ± 39.7 28.6 ± 14.1 0.161d 
Days to event 43.4 ± 26.0 38.2 ± 22.2 0.577 d 
Previous ESI 27 (27.6%) 9 (22.0%) 0.492b 
Duration (days) 43.0 (6-199) 30.5 (13-56) 0.236a 
Days to event 43.4 ± 26.9 42.8 ± 21.6 0.949d 
Pharmacologic profile     
Vitamin D 47 (47.5%) 27 (62.8%) 0.093b 
Previous antibiotic treatment 40 (40.4%) 15 (37.5%) 0.751b 
Duration (days) 38.7 ± 30.8 32.9 ± 20.7 0.525d 
Days to event 52.4 ± 32.6 30.9 ± 25.8 0.035d 
Biochemical profile     
HDL-Cholesterol (mg/dl)  45.0 (24-105) 49.0 (27-94) 0.039a 
Triglycerides (mg/dl)  150.0 (41-378) 153.0 (51-567) 0.568a 
PD-related variables    
PD duration (years) 1.0 (0-5) 1.0 (0-6) 0.841a 
Total Renal Clearance (ml/min)  4.17 (0.00-15.40) 2.81 (0.00-12.06) 0.107a 
Diuresis (ml) 1000 (0-3950) 750 (0-2500) 0.199a 
Total weekly Kt/V 1.80 (0.40-4.10) 2.20 (0.90-4.00) 0.022a 
Total Clearance (L/week) 93.0 (17.9-423.3) 86.6 (40.5-206.2) 0.692a 
D/P Cr (mg/dl)  0.78 (0.45-1.06) 0.79 (0.45-0.98) 0.683a 
ESI Outcome    
ESI Treatment    
Nº Total Antibiotics 2 (1-9) 3 (1-6) 0.029a 
Duration (days) 37.0 (14-198) 34.0 (14-199) 0.975a 
Tunnel infection 17 (54.8%) 4 (33.3%) 0.206b 
Peritonitis 5 (5.1%) 0 (0.0%) 0.323c 
Exit site cure 85 (85.9%) 33 (76.7%) 0.183b 
External Cuff Removal 5 (5.1%) 3 (7.0%) 0.698c 
Catheter substitution/removal 9 (9.1%) 7 (16.3%) 0.251c 
Hemodialysis/Renal Transplant 4 (4.0%) 1 (2.3%) 1.000c 
Results are expressed in: frequency (percentage); median (range); mean ± standard deviation. 
a Mann-Whitney U, b Chi-Square, c Fisher’s Exact Test,d T-test (unpaired groups). 
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Table IV: Comparison of patient characteristics between ESI caused by S. aureus and other agents 
Patient characteristic S.aureus P. aeruginosa p S. aureus Other G+ p S. aureus Non-S. aureus p 
Previous infections          
Previous Infections  14 (34.1%) 8 (36.4%) 0.860 b 14 (34.1%) 30 (49.2%) 0.133C 14 (34.1%) 44 (42.7%) 0.344b 
Duration (days) 61.3 ± 31.0 29.0 ± 15.4 0.022d 65.0 (11-128) 26.5 (5-199) 0.009a 65.0 (11-128) 28.5 (5-199) 0.003a 
Days to event 40.4 ± 29.5 33.0 ± 18.7 0.566d 40.4 ± 29.5 45.0 ± 24.5 0.643d 40.4 ± 29.5 42.7 ± 23.6 0.792d 
Previous ESI 10 (24.4%) 6 (28.6%) 0.722b 10 (24.4%) 18 (30.0%) 0.536b 10 (24.4%) 26 (25.7%) 0.867b 
Duration (days) 61.3 ± 31.0 34 ± 15.6 0.088d 65.0 (11-128) 28.5 (6-199) 0.021a 65.0 (11-128) 29.5 (6-199) 0.009a 
Days to event 40.4 ± 29.5 38.2 ± 17.9 0.883d 40.4 ± 29.5 45.3 ± 25.8  0.641d 40.4 ± 29.5 44.5 ± 24.2 0.659d 
Pharmacologic profile           
Vitamin D 15 (36.6%) 14 (60.9%) 0.061b 15 (36.6%) 33 (54.1%) 0.082b 15 (36.6%) 60 (57.7%) 0.022b 
Previous antibiotic treatment 13 (31.7%) 8 (36.4%) 0.709b 13 (31.7%) 28 (46.7%) 0.133b 13 (31.7%) 42 (41.6%) 0.274b 
Duration (days) 55.2 ± 31.5 41.4 ± 22.4 0.300d 55.2 ± 31.5 29.0 ± 25.7 0.014d 58.5 (5-116) 25.5 (5-119) 0.017a 
Days to event 47.9 ± 38.9 31.4 ± 25.0 0.303d 47.9 ± 38.9 53.5 ± 29.1 0.644d 47.9 ± 38.9 45.2 ± 29.8 0.800d 
Biochemical profile           
HDL-Cholesterol (mg/dl)  41.7 ± 9.0 50.6 ± 10.8 0.003d 41.7 ± 9.0 49.2 ± 15.6 0.007d 41.7 ± 9.0 50.6 ± 15.0 0.003d 
Triglycerides (mg/dl)  159.0 (67-378) 179.5 (51-567) 0.537a 178.3 ± 89.4 156.7 ± 67.2 0.219d 159.0 (67-378) 143.0 (41-567) 0.529a 
PD-related variables          
PD duration (years) 0.0 (0-2) 1.0 (0-6) 0.217a 0.0 (0-2) 1.0 (0-5) 0.002a 0.0 (0-2) 1.0 (0-6) 0.004a 
Total Renal Clearance (ml/min)  2.40 (0.00-12.88) 0.79 (0.00-8.56) 0.059a 2.40 (0.00-12.88) 4.99 (0.00-15.40) 0.031a 2.40 (0.00-12.88) 3.90 (0.00-15.40) 0.249a 
Diuresis (ml) 950 (0-3950) 300 (0-1950) 0.084a 950 (0-3950) 1150 (0-3000) 0.190a 950 (0-3950) 1100 (0-3000) 0.547a 
Total weekly Kt/V 1.68 ± 0.51 2.27 ± 0.67 <0.001d 1.70 (0.40-3.20) 2.00 (1.10-4.10) <0.001a 1.70 (0.40-3.20) 2.10 (0.90-4.10) <0.001a 
Total Clearance (L/week) 85.98 ± 44.33 83.91 ± 33.10 0.845d 75.95 (17.92-239.05) 111.30 (38.29-423.29) 0.003a 75.95 (17.92-239.05) 92.96 (38.29-423.29) 0.017a 
D/P Cr (mg/dl)  0.79 (0.63-1.06) 0.83 (0.45-0.98) 0.686a 0.79 (0.63-1.06) 0.78 (0.45-1.00) 0.245a 0.79 (0.63-1.06) 0.78 (0.45-1.00) 0.337a 
ESI Outcome          
ESI Treatment          
Nº Total Antibiotics 3 (1-9) 3 (1-5) 0.562a 3 (1-9) 2 (1-7) 0.001a 3 (1-9) 2 (1-7) 0.019a 
Duration (days) 49.0 (16-165) 32.0 (20-128) 0.046a 49.0 (16-165) 29.0 (14-198) 0.001a 49.0 (16-165) 31.0 (14-199) 0.001a 
Tunnel infection 12 (66.7%) 3 (33.3%) 0.127b 12 (66.7%) 6 (42.9%) 0.178b 12 (66.7%) 10 (37.0%) 0.050b 
Peritonitis 4 (9.8%) 0 (0.0%) 0.288c 4 (9.8%) 1 (1.6%) 0.155c 4 (9.8%) 1 (1.0%) 0.023c 
Exit site cure 32 (78.0%) 18 (78.3%) 0.984b 32 (78.0%) 55 (90.2%) 0.090b 32 (78.0%) 89 (85.6%) 0.272b 
External Cuff Removal 3 (7.3%) 0 (0.0%) 0.547c 3 (7.3%) 3 (4.9%) 0.682c 3 (7.3%) 5 (4.8%) 0.688C 
Catheter substitution/removal 6 (14.6%) 5 (21.7%) 0.505c 6 (14.6%) 4 (6.6%) 0.195c 6 (14.6%) 10 (9.6%) 0.389C 
Hemodialysis/Renal Transplant 2 (4.9%) 1 (4.3%) 1.000c 2 (4.9%) 2 (3.3%) 1.000c 2 (4.9%) 4 (3.8%) 1.000b 
Results are expressed in: frequency (percentage); median (range); mean ± standard deviation. a Mann-Whitney U, b Chi-Square, c Fisher’s Exact Test,d T-test (unpaired groups). 
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Table V: Comparison of patient characteristics between ESI with distinct outcomes 
Patient characteristic ≤30 days >30 days p Cured  Non-Cured p  
Previous infections       
Previous Infections  42 (40.8%) 39 (41.1%) 0.969b 80 (41.7%) 14 (50.0%) 0.405b 
Duration (days) 22.0 (4-70) 41.0 (8-199) 0.003a 27.5 (4-199) 37 (14-77) 0.185a 
Days to event 37.0 (10-94) 36.0 (5-93) 0.740a 36.0 (5-98) 19.5 (3-58) 0.027a 
Previous ESI 24 (23.8%) 29 (30.9%) 0.266b 50 (26.5%) 12 (42.9%) 0.073 
Duration (days) 23.0 (6-70) 42.0 (11-199) 0.001a 37.0 (14-77) 28.5 (6-199) 0.313a 
Days to event 33.0 (10-94) 36.0 (5-93) 0.820a 36.0 (5-98) 19.5 (3-58) 0.026a 
Pharmacologic profile        
Vitamin D 55 (51.9%) 55 (57.3%) 0.441b 109 (55.6%) 14 (48.3%) 0.459b 
Previous antibiotic 44 (43.6%) 37 (38.9%) 0.512b 80 (41.9%) 13 (50.0%) 0.433b 
Duration (days) 21.0 (5-72) 37.0 (5-119) 0.005a 25.0 (5-119) 37.0 (15-77) 0.029a 
Days to event 35.0 (0-113) 36.0 (0-133) 0.862a 40.0 (0-133) 18.0 (0-58) 0.006a 
Biochemical profile        
HDL-Cholesterol (mg/dl)  46.0 (27-105) 44.0 (24-105) 0.320a 45.0 (24-105) 49.0 (29-69) 0.547a 
Triglycerides (mg/dl)  133.0 ( 41-378) 158.0 (51-598) 0.047a 138 (41-567) 195.0 (51-598) 0.076a 
PD-related variables       
PD duration (years) 1.0 (0-6) 1.0 (0-6) 0.217a 1.0 (0-6) 1.0 (0-4) 0.581a 
Total Renal Clearance (ml/min)  4.11 (0.00-16.99) 3.37 (0.00-20.68) 0.121a 3.56 (0.00-20.68) 3.50 (0.00-15.97) 0.999a 
Diuresis (ml) 1125 (0-3950) 900 (0-2670) 0.187 a 950 (0-3950) 1150 (0-3000) 0.172a 
Total weekly Kt/V 2.00 (0.60-4.10) 1.80 (0.40-6.40) 0.081a 2.00 (0.40-6.40) 1.85 (0.90-3.60) 0.365a 
Total Clearance (L/week) 92.16 (19.46-423.29) 78.47 (17.92-284.34) 0.319a 87.78 (17.92-423.29) 89.99 (34.02-276.64) 0.800a 
D/P Cr (mg/dl)  0.78 (0.45-1.06) 0.78 (0.19-1.06) 0.991a 0.78 (0.19-1.06) 0.83 (0.70-1.02) 0.005a 
ESI Outcome       
ESI Treatment       
Nº Total Antibiotics 1 (1-4) 3 (1-9) <0.001a 2 (1-9) 3 (1-5) <0.001a 
Duration (days) - - - 29.0 (6-199) 51.5 (19-165) <0.001a 
Tunnel infection 9 (25.7%) 17 (47.2%) 0.060b 18 (29.0%) 11 (84.6%) <0.001b 
Peritonitis 3 (2.8%) 5 (5.2%) 0.481b 5 (2.6%) 3 (10.3%) 0.069C 
Exit site cure 102 (96.2%) 80 (83.3%) 0.002b - - - 
External Cuff Removal 0 (0.0%) 6 (6.3%) 0.011c - - - 
Catheter substitution/removal 4 (3.8%) 10 (10.4%) 0.063b - - - 
Hemodialysis/Renal Transplant 2 (1.9%) 3 (3.1%) 0.670c - - - 
Results are expressed in: frequency (percentage); median (range); mean ± standard deviation. 
a Mann-Whitney U, b Chi-Square, c Fisher’s Exact Test,d T-test (unpaired groups). 
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